DNA Polymerase Beta Catalytic and Fidelity Mutations Drive Platinum Specific Drug Sensitivity

With the advent of genome sequencing and its widespread use in the clinic, there is a great need to identify mutational biomarkers that predict therapeutic responses. DNA polymerase Beta (Pol{beta}) and the base excision repair (BER) pathway have been previously implicated as modulators of response to platinum-based chemotherapies and are mutated in as high as 30% of cancers. Here, we show in a triple-negative breast cancer (TNBC) model that two classes of mutations in Pol{beta}, reduced catalytic activity (E295K and D256A mutation) and reduced fidelity (I260M), are sufficient to drive cisplatin and carboplatin-specific sensitivity. Cellular response to oxaliplatin in these Pol{beta} mutant models is minimal relative to cisplatin and carboplatin. Additionally, we show that sensitivity is associated with reduced repair of both platinum-induced DNA intrastrand adducts and interstrand crosslinks (ICLs). Downregulation of the upstream BER factor uracil DNA glycosylase (UNG) reverses drug sensitivity consistent with these Pol{beta} mutations negatively impacting ICL DNA repair to drive drug sensitivity. In addition, intrastrand adduct repair readout indicates these lesions also play a role in the sensitivity observed in Pol{beta} mutant models. In vivo studies demonstrate a significant effect on tumor growth delay with cisplatin treatment in tumor xenografts harboring Pol{beta} mutations. These results support the potential for using Pol{beta} mutations as predictive biomarkers for cisplatin and carboplatin therapies in the clinical setting.